D E Shaw is a new public short seller in biotechnology company Hansa Biopharma with a position equivalent to 0.5 percent of the capital, compared with previously below 0.5 percent.
There are four public short sellers in the company. In total, 4.6 percent of the capital is shorted in the company.
The Swedish Financial Supervisory Authority requires positions above 0.1 percent to be reported, and short positions above 0.5 percent to be made public.
